

# Conclusions - Risk Assessment of T-2 and HT-2 mycotoxins in Food

## In this guide

### [In this guide](#)

1. [Background - Risk Assessment of T-2 and HT-2 mycotoxins in Food](#)
2. [Introduction - Risk Assessment of T-2 and HT-2 mycotoxins in Food](#)
3. [HBGV's established by EFSA - Risk Assessment of T-2 and HT-2 mycotoxins in Food](#)
4. [Exposure assessment - Risk Assessment of T-2 and HT-2 mycotoxins in Food](#)
5. [Risk characterisation - Risk Assessment of T-2 and HT-2 mycotoxins in Food](#)
6. [Conclusions - Risk Assessment of T-2 and HT-2 mycotoxins in Food](#)
7. [Abbreviations - Risk Assessment of T-2 and HT-2 mycotoxins in Food](#)
8. [References - Risk Assessment of T-2 and HT-2 mycotoxins in Food](#)

60. Based on the acute risk assessment, it is unlikely that there is an acute health concern to UK consumers. Mean estimates of total acute exposure to T2/HT2 across the diet are below the ARfD and given the uncertainties in the data it is unlikely that the exceedances for 97.5<sup>th</sup> percentile estimated exposures pose a significant risk to consumers.

61. While the same uncertainties apply to chronic exposure estimates, the estimated chronic exposures to T2/HT2 significantly exceed the TDI, at mean but especially high consumption. A health concern to the UK population can therefore not entirely be excluded.

62. However, it should be noted that the sample size making up the sum of processed foods is very small and may therefore not be representative.

## Questions on which the views of the Committee are sought:

63. Members are invited to consider the following questions:

i) Given the uncertainties of the exposure assessment, do Members consider there to be a health risk associated with:

- any of the exceedances of the ARfD shown in Table 3?
- any of the exceedances of the TDI shown in Table 4?

ii) Would the Committee like to see any further information or data analysis to support this risk assessment, such as annual trend analysis?

**Secretariat**

**June 2024**